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SurgicalSolutions
High Volume, Top Quality, and Rigorous Research:
Jefferson Sets New Standards in Pancreatic Cancer Care
Each year, Jefferson surgeons perform
over 200 pancreatic resections,
including more than 130 “Whipple
procedures” — making the hospital #1
in surgical volume for pancreatic
cancer and related diseases in the
tristate region of Pennsylvania,
New Jersey and Delaware.
“While we are very proud of what
we have achieved, there are always
opportunities for improvement,” says
Charles J. Yeo, MD, FACS, Samuel D.
Gross Professor and Chair of Surgery,
who has personally performed more
than 1,400 Whipple procedures and
treated thousands of patients with
pancreatic cancer and related diseases.
Beyond the impressive numbers, the
Jefferson Pancreas, Biliary and Related
Cancer Center offers much more:
multidisciplinary diagnosis and
treatment, groundbreaking clinical
research, and active involvement in
community events — such as Amy’s
Ride/Run/Walk in Quakertown (May
20) and Pancreatic Cancer Action
Network’s PurpleStride (November 4).
New Multidisciplinary Pancreatic
Cancer Clinic
When pancreatic cancer is suspected,
many patients and their families feel
overwhelmed. In addition to the
emotional impact, patients may have to
schedule several appointments to see
primary doctors and gastroenterologists,
as well as surgeons, medical oncologists
and radiation oncologists. At our
Multidisciplinary Pancreatic Cancer
Clinic, all relevant clinicians gather
each Monday afternoon to review
cases and see patients — providing
the convenience of multiple
appointments during a single visit.

for Research in the Department of
Surgery, has been building a worldclass pancreatic cancer research
program. Dr. Brody specializes in
studying the molecular basis of
cancer development and progression,
targeted therapy and personalized
medicine. As a translational researcher,
he steers the research trajectory of
the Brody Laboratory while serving
as an advisor/collaborator to all
levels of trainees as well as our
practicing surgeons, including Drs.
Harish Lavu and Jordan Winter.
Ongoing Clinical Trials
Harish Lavu, MD, FACS, is leading the
Whipple Accelerated Recovery Pathway
(WARP) trial aimed at supporting faster
recovery from pancreatic surgery. In
2007, the team conducted a similar
study that established the seven-day
“Critical Pathway” standard at Jefferson.
The WARP trial — initiated in late 2015
and with nearly 70 patients enrolled
to date — is testing a five-day pathway.
The protocol incorporates in-hospital
physical therapy, specific dietary
recommendations and rigorous
monitoring following discharge.

Our multidisciplinary pancreatic cancer team includes surgeons, GI specialists, medical oncologists,
radiation oncologists, advanced practice nurses, research scientists, residents, postdoc fellows, graduate
students, clinical research coordinators and nutritionists.

“In Asia, average hospital stay for pancreatic surgery patients is 21 days.
In Europe, it’s 14 days. In most U.S. hospitals, it’s 12 to 14 days. Here at
Jefferson, our current seven-day stay requires tremendous coordination
across the Surgery, ICU and Nursing teams. With the WARP trial, we are
trying to do something few others have consistently been able to do:
improve outcomes by safely discharging Whipple procedure patients
after just 5 days.
“Why are shorter hospital stays better? Research has shown that being in a hospital when you
aren’t critically ill actually delays healing and exposes patients to hospital-acquired infections.
We want to prepare our patients to leave the hospital as quickly as possible so they can recover
safely and more rapidly in the comfort of their own homes.”

Development of a National Cancer
Institute Funded Research Program

Meanwhile, Jordan M. Winter, MD,
FACS, is tackling a perennial patient
query: “Can pancreatic surgery make
the cancer ‘spread’?” To explore this
topic, Dr. Winter is leading the Water
or Saline at High Volumes (WASH)
trial that is testing the use of 10 liters of
plain water or salt water for abdominal
washing immediately following removal
of the tumor. Current practice uses
just one or two liters of saline at the
conclusion of the procedure. The
study, started in April 2016 with more
than 100 patients enrolled to date,
aims to expand to other sites and
enroll 800 patients.

Since his recruitment in 2006,
Jonathan Brody, PhD, Vice Chair

For more information, go to
Jefferson.edu/Pancreas.
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“Lymphatics, nerves, small blood vessels and tumor margins frequently
have cancer in them, which can only be appreciated at the microscopic
level. As we’re dividing these structures, can some of these cells be
spilled? It isn’t inconceivable. The hypothesis of the WASH study is that
this high-volume washing may remove those kinds of free-floating
cancer cells present after the tumor is resected – ultimately helping to
prolong survival.
“Very few surgical cancer studies have looked specifically at pancreatic cancer outcomes.
This trial points to the potential for surgical oncologists to affect cancer outcomes with an
inexpensive intervention: high-volume abdominal washing. If we can use it to improve survival
even by a few months, we’re accomplishing the same thing as a billion-dollar drug.”
Jordan Winter, MD, FACS
Associate Professor
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